Archive › JAZZ

JAZZ trade ideas: every closed DuckWise idea on Jazz Pharmaceuticals plc

DuckWise has published 1 idea on Jazz Pharmaceuticals plc (JAZZ, Stock) that has closed between June 2020 and October 2020. Each is listed below with the levels published before the position was taken and its result at close — 1 in profit, 0 at a loss.

Prices in US dollars. Result is the price change from the published entry to the published close, before fees, taxes and slippage. How results are counted.

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. Does not pay dividends.

These are closed ideas, published for the record. They are general and impersonal research, not a recommendation to buy or sell JAZZ or any other security.